))
DME/Retina Edition: Top Headlines for Week of July 8, 2024
Manage episode 428373684 series 3560281
Conteúdo fornecido por Healio. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Healio ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:
FDA approves Vabysmo prefilled syringe for retinal diseases
VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates
FDA approves Eylea biosimilar FYB203/Ahzantive
VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study
ANI Pharmaceuticals to acquire Alimera Sciences
References:
Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Healio Interviews
Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.
118 episódios
Compartilhar
